I checked into it last year. This was an over exuberant person updating another website that made the mistake. It wasn't Dr Menon's fault. It was corrected and removed once pointed out. All you see now are cached copies from before the correction.
The science will end up drowning the noise out. If the science isn't there the stock goes down either way. That is why I'm so happy to see the Brilacidin phase IIb has done so well. It derisked the stock.
In Reply to 'frrol'
That lie about his academic credentials is troubling though, I wish he would address it (clear it up or remove it). Lies hurt credibility. If Kevetrin results are positive, the issue will become less relevant of course. Until then though, his word is not good. And he gives fodder for legitimate criticism that affects our stock price and cost of capital. I'm going to write the company and ask, unless someone has already got a response from them on this matter?
News 
Market Data 
Discover 
AI
